Drug Trial Radar · NCT05504278
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
144
Planned (sponsor's estimate)
Start
Sep 20, 2022
Primary completion
May 31, 2025
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase Ib/III study evaluates the efficacy and safety of IBI351 in combination with chemotherapy in advanced non-squamous NSCLC with KRAS G12C mutation.
Conditions
- Advanced Non-Small Cell Lung Cancer
Interventions
IBI351Drug
recommended dose, po
CetuximabDrug
500mg/m\^2, Q2W, day1, i.v.
pemetrexedDrug
500mg/m\^2, Q3W, day1, i.v.
CarboplatinDrug
AUC=5, Q3W, day1, i.v.
SintilimabDrug
200mg, Q3W, day1, i.v.
cis-platinumDrug
75mg/m\^2, Q3W, day1, i.v.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose limiting toxicityTime frame: 12 months
- Evaluate clinical efficacy of IBI351 in combination with other therapeutic agentsTime frame: 24 months
- Safety indicators during the introduction phase for IBI351 combination treatment :Time frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jilin Province Cancer Hospital
Jilin City, Changchun, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.